• Share
  • Email
  • Embed
  • Like
  • Save
  • Private Content
Tyler J. Curiel, MD, MPh.doc
 

Tyler J. Curiel, MD, MPh.doc

on

  • 2,824 views

 

Statistics

Views

Total Views
2,824
Views on SlideShare
2,824
Embed Views
0

Actions

Likes
0
Downloads
11
Comments
0

0 Embeds 0

No embeds

Accessibility

Upload Details

Uploaded via as Microsoft Word

Usage Rights

© All Rights Reserved

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
    Processing…
Post Comment
Edit your comment

    Tyler J. Curiel, MD, MPh.doc Tyler J. Curiel, MD, MPh.doc Document Transcript

    • CURRICULUM VITAE TYLER JAY CURIEL Home address: 219 Park Hill Drive San Antonio, TX 78212 Business address: University of Texas Health Science Center 2040 Babcock Road, suite 201 San Antonio, TX 78229 Telephone: 210-562-5287 Fax: 210-562-5292 E-mail: curielt@uthscsa.edu PERSONAL HISTORY Date of birth: March 31, 1956 Marital status: Married, two children UPIN D3350 Medicare provider number: 4E356 Present positions: Professor Department of Medicine Division of Hematology/Medical Oncology Citizenship: American EDUCATION HISTORY 1977 BS summa cum laude, with highest honors, with honors in chemistry, University of Georgia, Athens, GA 1982 MD Duke Medical School, Durham, NC 1983 MPH Harvard University, Boston, MA Internship and Residency: 1983-1984 Intern in Medicine, Yale Medical School and Yale-New Haven Hospital, New Haven, CT 1984-1986 Resident in Medicine, Yale-New Haven Hospital, New Haven, CT 1
    • FELLOWSHIPS 1980-1981 Special Research Fellow in Infectious Disease, Duke Medical School, Durham, NC. Research mentor: Dr. David T. Durack, MD, DPhil 1986-1990 Clinical and Research Fellow in Infectious Diseases, Harvard Medical School and Massachusetts General Hospital, Boston, MA 1986-1990 Research Fellow in Medicine, Harvard Medical School, Boston. Research mentors: Drs. Robert Schooley, MD and Bruce Walker, MD 1995-1997 Clinical and Research Fellow in Medical Oncology, University of Colorado Health Sciences Center, Denver, CO SPECIALTY CERTIFICATION 1984 Diplomate, American Board of Internal Medicine, number 245997 1986 American Board of Internal Medicine, number 106733 1988 American Board of Infectious Diseases, number 106733 1999 American Board of Medical Oncology, number 106733 LICENSURE 1984 Connecticut State Board of Medical Examiners No. 26470 inactive 1986 Massachusetts State Board of Medical Examiners No. 56080 inactive 1991 Colorado State Board of Medical Examiners No. 30641 exp 5/31/09 2000 Texas State Board of Medical Examiners No. L0112 exp 3/31/10 2002 Louisiana State Board of Medical Examiners No. 14342R exp 3/31/09 PROFESSIONAL POSITIONS 1983 Hospital epidemiologist and attending physician, Hospital Infantil Robert Reid Cabral, Santo Domingo, Dominican Republic 1983 Attending physician, Pediatric Infectious Disease Division, Hospital Infantil Robert Reid Cabral, Santo Domingo, Dominican Republic 1985-86 Consultant in Medicine, Gaylord Rehabilitation Hospital, Wallingford, CT 1987-90 Consultant in Medicine, Massachusetts Eye and Ear Infirmary, Boston, MA 1990 Instructor in Medicine, Harvard Medical School, Boston, MA 2
    • 1990-93 Chief Infectious Disease Consultant, Bone Marrow Transplantation Unit, University of Colorado Health Sciences Center, Denver, CO 1990-97 Attending physician, Medical Service and Division of Infectious Diseases, University of Colorado Health Sciences Center, Denver, CO 1990-97 Attending physician, Division of Infectious Diseases, Veterans' Affairs Medical Center, Denver, CO 1990-96 Chairperson, Infection Control, University Hospital, Denver, CO 1990-97 Assistant Professor of Medicine (Infectious Diseases), University of Colorado Health Sciences Center, Denver, CO 1992-94 Assistant Director for Basic Science Research, Bone Marrow Transplantation Unit, University of Colorado Health Sciences Center, Denver, CO 1992-94 Director, Core Human Immunology Laboratory, Cancer Center University of Colorado Health Sciences Center, Denver, CO 1993-97 Assistant Professor of Immunology, University of Colorado Health Science Center Graduate School of Immunology, Denver, CO 1995-97 Assistant Professor of Medical Oncology, University of Colorado Health Sciences Center, Denver, CO 1996-97 Program co-Director, and Basic Science Director, AIDS-Related Malignancy Program, UCHSC Cancer Center, Denver, CO 1997-2001 Associate Investigator, Baylor Institute for Immunology Research, Dallas, TX 1998- Associate Professor, Graduate Program in Biomedical Sciences, Baylor University, Waco, TX 2001-2003 Associate Professor of Medicine, Tulane University School of Medicine School, New Orleans, LA 2001- Section Chief, Hematology and Medical Oncology, Tulane University School of Medicine, New Orleans, LA 2001- The Henderson Chair in Medicine, Tulane University School of Medicine, New Orleans, LA 3
    • 2002-2003 Associate Professor of Cell and Molecular Biology, Tulane University, New Orleans, LA 2002-2003 Clinical Associate Professor of Obstetrics and Gynecology, Tulane University School of Medicine School, New Orleans, LA 2001-2003 Associate Professor of Medicine with tenure, Tulane University School of Medicine School, New Orleans, LA 2003-2006 Professor of Medicine with tenure, Tulane University School of Medicine School, New Orleans, LA 2003-2006 Clinical Professor of Obstetrics and Gynecology, Tulane University School of Medicine, New Orleans, LA 2003-2006 Professor of Cell and Molecular Biology, Tulane University, New Orleans, LA 2005-2006 Director, Tulane/LSU General Clinical Research Center, Medical Center of Louisiana (Charity Hospital) and Tulane University, New Orleans, LA 2005-2006 Visiting Clinical Professor of Medicine and Member, University of Colorado School of Medicine, Denver, CO and the Anschutz Cancer Center, Aurora Colorado 8/2006- Adjunct Professor of Medicine, Tulane Medical School 8/2006-12/07 Director, San Antonio Cancer Institute UTHSCSA 8/2006-12/07 Scientific Director Center for Treatment & Research on Cancer San Antonio, TX 8/2006-3/2007 Interim Chief, Division of Medical Oncology University of Texas Health Sciences Center 8/2006- Dielmann Professor of Medicine University of Texas Health Sciences Center San Antonio (UTHSCSA) 8/2007- Max and Minnie Tomerlin Voelcker Distinguished University Professor of Targeted Cancer Therapy, UTHSCSA 8/2006- Assistant Dean for Oncology, UTHSCSA 12/07-2/08 Director, Cancer Therapy & Research Center at the UTHSCSA 4
    • UTHSCSA 2/08-10/09 Executive Director, Center for Cancer Therapy & Research, UTHSCSA 2/08-10/09 Scientific Director, Center for Cancer Therapy & Research, UTHSCSA AWARDS AND HONORS 1974 Gordon P. Watson Award (Outstanding Freshman) 1977 Honors Graduate in Chemistry 1977 Phi Beta Kappa 1977 Phi Kappa Phi 1977 Sigma Xi 1979 Lane Memorial Scholarship (Duke) 1981 Alpha Omega Alpha Honor Medical Society 1996 Certificate of Commendation from the Medical Staff, University of Colorado Health Sciences Center 1996 Certificate of Commendation from Hospital Administration, University of Colorado Health Sciences Center 2001 Research chosen for the cover of the 2001 Tulane Medical School Annual Research Report 2002 Focused Giving Award recipient, Johnson and Johnson Corporation 2002 Picture chosen for the cover of the 2002 Tulane Health Sciences Center Annual Report 2002 Bouquet Award for civic service from The Gambit weekly newspaper of New Orleans, LA 2003 Research chosen for the cover of the 2003 Tulane Medical School Annual Research Days Program Book 2003 Mauvernay Research Excellence Award (includes $500 prize) from Tulane University 2003 Featured person in Living section of the New Orleans Times-Picayune newspaper. August 9, 2003, page E1. 2003 Bouquet Award for civic service from The Gambit weekly newspaper of New Orleans, LA 2004 Featured person in “Random Samples”. Science. 2004;303:37. 2004 Featured person in La Prensa. Spanish language newspaper of Louisiana area. February 2004, p. 30-34. 2004 New Orleans Business Innovator of the Year Honorable Mention (shared with Andy Martin for co-founding Bounce for LifeTM non-profit cancer research organization) 2004 Mauvernay Grand Prize for Cancer Research from Tulane University. (Includes a $5000 award). 2005 New Orleans Business Innovator of the Year (shared with Andy Martin for co-founding Bounce for LifeTM non-profit cancer research organization) 2005 Leonard Tow Humanism in Medicine Award from Tulane Medical School 5
    • 2005 Inductee, Arnold P. Gold Foundation for Humanism in Medicine 2006 Bouquet Award for civic service, The Gambit Weekly, New Orleans, LA 2006 Featured scientist, NovaNow Science Programs, Public Broadcasting System 2006 STARS Research Enhancement Award from the University of Texas System PROFESSIONAL SERVICE AND COMMITTEES Institutional and Departmental: 1991-95 Drug Utilization and Evaluation Committee 1992-95 Women in Medicine Committee 1997-2001 Biosafety Officer, Baylor Institute for Immunology Research 2001 Baylor Institutional Animal Care and Utilization Committee 2001- Tulane Cancer Center Steering Committee 2001- Tulane Medical Center Internship and Residency Selection Committee 2001- Tulane Medical School MD/PhD Program, Admissions Committee Steering Committee for the Cancer Research Consortium of Louisiana at New Orleans 2001- Member, Cancer Research Advisory Board, Tulane Cancer Center 2002- Tulane Hospital Cancer Committee member Tulane Cancer Center Site Leaders, Chairman of Immunotherapy Group 2002- Tulane Cancer Center, Program Leader for Phase I/II Studies 2002- Louisiana Cancer Research Consortium at New Orleans, Director of Program in Immunology, Tulane component 2003 Member, Search Committee for Associate Senior Vice President or Research, Tulane University 2003 Co-Moderator, Poster Discussions for Tulane Research Days 2003 Research Judge, Tulane Annual Research Days Program 2003 Member, Pulmonary Chief Search Committee, Tulane Medical School 2003 Member, Search Committee for Associate Vice President AVP for Technology Transfer and Business Development, Tulane University 2003 Chair, Infectious Diseases Chief Search Committee, Tulane University 2003- Treasurer, Alpha Omega Alpha Honor Medical Society, Tulane Chapter 2003 Development Committee, The TUHSC Auxiliary Award for Excellence in Research 2003 Development Committee, Charles B. Henriques Award for Excellence in Research 2005 Tulane Research Space Committee 2005 Member, Pediatrics Chairman Search Committee, Tulane Medical School 2006 Member, Faculty Compensation and Incentive Plan Committee, Tulane Medical School 2006 Member, Research Evaluation and Strategic Plan Committee, Tulane Medical School 2006 Member, South Texas Research Facility Planning Committee, UTHSCSA 6
    • 2007 Member, chief of surgical oncology search committee, UTHSCSA 2008 Member, search committee, dean of the graduate school of biomedical sciences, UTHSCSA Regional: 2002- Abstract Reviewer, Southern Society of Clinical Medicine Regional Meetings 2002- Member, SWOG Immunomolecular Therapeutics Committee National: 1993-96 Vice Chairperson, Cellular Immunity Working Group, AIDS Clinical Trials Group (ACTG) 1993-96 Ad Hoc Member, NK Cytotoxicity Quality Assurance and Assay Standardization Committee, (ACTG) 2008-2010 Member, Scientific Program Committee in Developmental Therapeutics- Immunotherapy, ASCO International: 2002-2004 Planning Committee, 2004 International Society for Experimental Hematology International Meeting, New Orleans, LA. July 2004. PATENTS 1. "Compositions and Method for Inhibition of HIV Production." G. S. Harrison, I. H. Maxwell, T. J. Curiel and F. Maxwell. This patent describes the concept of HIV- regulated diphtheria toxin A subunit as an HIV gene therapy, and describes technical details related to expression cassette design and production. U.S. patent number 5,554,528. Issued 9/93. 2. “Inhibition of Toxoplasma gondii replication by pyridinylimidazoles”. T. J. Curiel. This application describes the actions of pyridinylimidazoles on the inhibition of growth of medically important intracellular parasites. Patent 6,649,637 issued November 18, 2003. 3. Composition of dendritic cell binding peptides. T. J. Curiel, C. Morris, M. Zadeh. This application describes novel 12-mer peptides that specifically bind to Langerhans dendritic cells or to interstitial dendritic cells. They are useful for vaccines, and to isolate dendritic cells. Provisional patent filed 4-03. Full application filed 4-04. REVIEW AND REFEREE ACTIVITIES Grants 7
    • Local: 1993 Internal grant reviewer, Gene Therapy Core, Cancer Center, University of Colorado Health Sciences Center, Denver, CO 2002- Internal grant reviewer, Tulane Cancer Brown Endowment Matching Grants, Tulane University School of Medicine, New Orleans, LA 2003 Tulane Research Days research judge State: 2002-2006 Louisiana State Task Force on Bioterrorism Regional: 2003-2006 Southern Society for Clinical Investigation abstract reviewer for meeting National: 1997 NIAID Novel AIDS Vaccines Initiative ad hoc 1997-2001 Veteran's Affairs MERIT Grants 1998 NHLBI Immune Defenses in Pulmonary Infections ad hoc 2001 NIAID PA-01-075 Mucosal HIV infection ad hoc 2002 NCI SRG-Subcommittee C, Basic and Preclinical Sciences (P30 Program) ad hoc 2003 NCI SRG-Subcommittee C, Basic and Preclinical Sciences (P30 Program) ad hoc 2003 NIH Experimental Immunology Study Section ad hoc 2003 NIH AITC (P30 Program) Tumor Immunology ad hoc 2003 NIH NIAID ZRG1 SSSF (01) Special Emphasis Panel on AIDS- related Infections ad hoc 2004 ZAI1 KS-I (J1) Special Emphasis Panel/Initial Review Group for cancer P01 ad hoc 2005 COI (C) Special Emphasis Panel/Initial Review Group for HCV Center of Excellence U19 8
    • 2005 Congressionally Directed Medical Research Programs in Ovarian Cancer 2005 External Reviewer for Morehouse School of Medicine Minority Biomedical Research Support Program 2006 Ad hoc reviewer, NIAID ACTU initiatives Special Emphasis Panel ZAI1 MPM-A-M1 2006 Ad hoc reviewer, NIAID ACTU initiatives Special Emphasis Panel ZAI1 SR-A-M3 2006- Ad hoc reviewer, NCI, Tumor Microenvironment (TME) Study Section 2008 Ad hoc reviewer, NCI, Cancer Center Review Panel 2008 Ad hoc reviewer, DARPA, prostate cancer grants Journals Ad Hoc Reviewer: AIDS AIDS Newslink AIDS Research Human Retroviruses American Board of Internal Medicine (Subspecialty Boards in Medical Oncology) American Journal of Pathology Ashley Publications (Immunology Reviews) Bone Marrow Transplantation British Medical Journal British Journal of Cancer Cancer Research Cellular Immunology 9
    • Cellular and Molecular Immunology Clinical Cancer Research Clinical and Experimental Immunology Clinical Immunology Clinical Immunology and Immunotherapy Clinical Microbiology Reviews Contemporary Oncology Elsevier Publications Books Haematologica International Journal of Cancer International Journal of Parasitology Journal of Clinical Investigation Journal of Immunology Journal of Infectious Diseases Journal of Leukocyte Biology Journal of Molecular and Cellular Biology Microbes and Infection Nature Reviews Cancer Nature Reviews Immunology New England Journal of Medicine Parasitology Today Perspectives Proceedings of the National Academy of Sciences (USA) 10
    • Tumor Targeting Editorial Boards: Frontiers in Bioscience 1998-2003 Tumor Targeting 1999-2003 Associate editor, Journal of Immunology 2005- Editorial Board, Clinical Medicine: Oncology 2007- PROFESSIONAL ASSOCIATIONS American Association of Immunologists member #208840 American Association for the Advancement of Science #03161226 Southwest Oncology Group American Society of Clinical Oncology member #37686 American Society for Hematology member American Association of Cancer Research member #124869 Gynecologic Oncology Group Southern Society of Clinical Investigation European Society of Gynaecologic Oncology member #0560 European Society for Cancer Immunology and Immunotherapy TEACHING ACTIVITIES Graduate and Medical School Lectures: 1983 Lecturer, Public Health, Epidemiology, Statistics and Immunology, Universidad Mundial, Santo Domingo, Dominican Republic 1989 Lecturer, Harvard School of Public Health, Divisions of Maternal Studies and Population Science, Boston, MA 11
    • 1990 Lecturer, Infectious Diseases, Postgraduate Course, Massachusetts General Hospital/Harvard Medical School, Boston, MA 1990-97 Lecturer, Health Professionals Continuing Medical Education, University of Colorado Health Sciences Center, Denver, CO 1990-97 Lecturer, Infectious Disease Pathophysiology Course for second year medical students, University of Colorado Medical School, Denver, CO 1990-97 Designated speaker for the Infection Control Committee to Housestaff. I gave lectures on Infection Control-related issues to all incoming housestaff yearly at orientation, and topic-specific seminars throughout the year on an as-needed basis. 1992-97 Lecturer, IDPT 7664, a graduate seminar "Immune responses to infectious agents and immunopathology." The Graduate School of Microbiology and Immunology, University of Colorado, Denver, CO 1998-2001 Research Mentor, University of Texas Waco Program in Biologic Sciences. Rotating lectures in Immunology and Microbiology to the graduate students. Allow graduate students to rotate through my laboratory. 2000-2001 Graduate seminar in immunology lecturer at Baylor University. Gave immunology lectures to first and second year graduate students in Biomedical sciences. 2002- Graduate seminar in tumor immunology at Tulane Medical School. This is a special seminar for graduate students in the Program in Cell and Molecular Biology, and the School of Public Health. 2003 Lectures to Tulane second year medical students in leukemias and lymphomas 2004 Lecture to LSUHSC-NO graduate students in MIP Program on tumor immunology. March 22 and March 26, 2004. 2006 Immunology lecturer, National Jewish Center for Immunology and Pulmonary Diseases, Denver, CO. A series of lectures to graduate students in the immunology program. 2008- Immunology lecturer, UTHSCSA graduate school in biomedical sciences. Micr 5003/5027: Fundamental Concepts in Microbiology and Immunology Premedical Student Preceptor: 12
    • 1992-97 Preceptor and lecturer, NIH Minority Student Enrichment Program. This program is for college level students wishing to pursue a career in biomedical sciences. Responsibilities include giving one lecture (on HIV disease), and acting as research preceptor for a student rotating through the lab. 1993-97 Preceptor and lecturer, minority high school student program. This is essentially the same program as above, designed for high school students. 2002 Preceptor for Xavier University (New Orleans) summer internships for minority students interested in biomedical careers. Students rotate through our laboratories and do hands-on work. 2002-2006 Immunology preceptor of Tulane undergraduate students Medical Student Preceptor: 1986-1990 Preceptor, Introduction to Clinical Medicine, a course for second year Harvard medical students. I provided hands-on clinical examination exercises for groups of four students. 1991-97 Oral final exam preceptor for third year University of Colorado Health Sciences Center medical students completing the required General Internal Medicine rotation. 2002-2006 Introduction to Clinical Diagnosis. Physical diagnosis and history taking at the bedside for Tulane Medical School, second year students. 2003-2006 Clinical Decision Making Journal Club. A small group forum for discussing medical literature and how to interpret study design for second- year Tulane Medical students. 2003-2005 Preceptor for medical students in the Tulane Medical School summer research fellowship. 2004-2006 Clinical Mentorship program mentor for Tulane Medical students 2004 students: Sukhwant Singh, T-3 ; Lena J. Gamble, T-2; Jason Prior, T-2. Graduate Student Preceptor: 1992-1996 Research advisor and rotating laboratory experience mentor to graduate students, the Graduate Program in Immunology, University of Colorado Health Sciences Center, Denver, CO 13
    • 1993-97 Research advisor, Infectious Disease fellowship training program, the Children's Hospital and University of Colorado Health Sciences Center, Denver, CO 2000-2007 Research advisor and rotating laboratory experience mentor to graduate students, the Graduate Program in Biomedical Sciences, Baylor University, Waco, TX 2001-2003 Thesis committee, Stephanie Carmichael, PhD candidate, Tulane Graduate School (Biochemistry). “The influence of antigen three-dimensional structure on helper T cell epitope immunodominance” PhD awarded April 2003. 2003-2005 Thesis committee, Margaret Parks, PhD candidate, Tulane Graduate School (Genetics). “Apoptosis in cystinosis”. PhD awarded June 2005. 2007- Thesis advisor, Suzanne Thibodeaux, candidate for PhD, UTHSCSA. “The role of B7-H1 signals in cancer” 2007- Thesis advisor, Pei Yi Lin, candidate for PhD, UTHSCSA. “Non-Treg regulatory cells in cancer”. Former Trainees: Elizabeth McFarland, MD 9/90-8/91 Project: CTLs in pediatric HIV infection Position: post-doctoral Infectious Disease Fellow, UCHSC Current position: Assistant Professor of Pediatrics, UCHSC. Assistant Director, Immunodeficiency Clinic, the Children's Hospital, Denver, CO. Pascal Poignard, PhD 11/90-10/91 Project: cellular immunity to T. gondii Position: visiting scientist, UCHSC Infectious Disease Division Current position: Scientist, Torrey Pines Research Institute, La Jolla, CA Elizabeth Connick, MD 7/91-6/94 Project: immune responses in acute HIV infection Position: post-doctoral Infectious Disease Fellow, UCHSC Current position: Associate Professor of Medicine, University of Colorado Health Sciences Center, Denver, CO Paul Nash, PhD 1/94-10/96 Project: apoptosis in T. gondii infected cells; animal vaccine models. Position: post-doctoral fellow in Immunology, Graduate Program in Immunology, University of Colorado, Denver, CO. Current position: Research Scientist, Heska, Inc., Ft. Collins, CO 14
    • Penelope Clarke, PhD 2/96-9/97 Project: development of recombinant T. gondii; cloning novel T. gondii genes Position: Research associate, UCHSC Current position: unknown Myra Morgan, MD 8/95-6/98 Project: role of EBV in B cell lymphomas, immunity in bone marrow transplant Position: Infectious Disease Fellow, UCHSC Current Position: Associate Professor of Medicine University of Michigan Medical Center, Ann Arbor, MI Tatyana Isaeva, MD, PhD 7/99-7/01 Project: Myeloid dendritic cells in ovarian and other carcinomas Position: junior research fellow, BIIR Current Position: Staff Scientist, UAB Gene Therapy Program, Birmingham, AL Weiping Zou, MD, PhD 3/99-8/01 Project: Differentiation of myeloid and lymphoid human dendritic cells in cancer Position: post-doctoral fellow, BIIR Current Position: Associate Professor of Medicine with tenure, Tulane Medical School Charlie Branson, BS 6/00-8/00 and 12/00-8/01 Project: SDF-1 and T cell immunity in ovarian carcinoma Position: candidate for MS, UT Waco Current Position: unknown Hania Wehbe, BS 6/01-8/01 Project: immunity to ovarian carcinoma Position: candidate for PhD, UT Waco Current Position: candidate for PhD, UT Waco Carla Zimmerman, BS 6/02-1/03 Project: DCs in ovarian cancer Position: graduate student, Tulane Shuang Wei, PhD 6/99-12/03 Senior post-doctoral fellow, Tulane Medical School Project: Regulation of differentiation of human dendritic cells Current position: Instructor in Medicine, University of Michigan Michael Brumlik, PhD 4/03-12/03 Project: cloning of a novel T. gondii MAP kinase Position: Research Associate Current Position: Assistant Professor of Medicine, tenure track, UTHSCSA 15
    • Joel Greco 3/03-5/03 Tulane PhD candidate. B7-H1 regulation in Toxoplasma gondii infection. Current position: Tulane PhD candidate Erin Coakley 9/02-5/03 Tulane Medical student. Role of SDF-1 in ovarian cancer pathogenesis. Current position: intern in medicine, Tulane Medical School Jason Prior 6/03-8/03 Tulane Medical student, second year B7-H1 signals in Toxoplasma infection Current position: medical student, Tulane medical school Janis Taube, MS 6/03-12/03 Tulane fourth year medical school student Immunologic effects of nucleated red blood cells Current position: Junior resident in Pathology, Johns Hopkins Charla Poole 6/03-8/03 Tulane Medical School MD, PhD student Estrogen signals in dendritic cell dysfunction Current position: MD/PhD student, Tulane Alexander Hillel 9/03-4/04 Tulane fourth year medical school student CD40 signals in cancer pathogenesis Current position: Junior resident in ENT surgery, Johns Hopkins Kirshma Kehmani 9/03 to 5/04 Tolerance to BMT Current position: Medical Student, St. Georges Andrew Martin 9/03-8/04 Tulane second year medical school student studies of sinonasal undifferentiated carcinoma Current position: deceased Nikki Singh Tulane senior medical student Regulatory T cells in ovarian cancer Current position: resident in Medicine, Oregon Health Sciences Center Marisa Toups Tulane senior medical student studies of sinonasal undifferentiated carcinoma 16
    • Current position: intern in surgery, UAB Rahul Dalvi, MD 7/04- 6/05 Post-doctoral fellow Studies of sinonasal undifferentiated carcinoma Current position: resident in medicine, LSU-NO Rachael Yenni 9/04- 8/05 Tulane University senior undergraduate student Role of a novel T. gondii MAP kinase in virulence Current position: PhD candidate, Tulane Graduate School Suzanne Thibodeaux 9/02-6/05 Tulane undergraduate student Regulation of B7-H1 in T. gondii infection Current position: MD/PhD student, UTHSCSA Rebecca Kruse-Jarres, MD 5/05- Hematology and Medical Oncology fellow Tolerance to factor VIII in hemophilia Current position: Clinical Assistant Professor of Medicine (Heme/Onc) Tulane Medical School Holly Murphy, MD 5/05-3/08 Regulatory T cells in HIV pathogenesis Current position: Instructor in Medicine, Tulane Medical School K23 mentee Brian Barnett, MD 7/03-12/05 Post-doctoral fellow, Tulane Medical School Immunopathogenesis of ovarian cancer Current position: Assistant Professor of Medicine (Heme/Onc), Tulane Medical School Ben Daniels, BS 6/00-8/00 and 5/01- 5/05 Project: immunity to Toxoplasma gondii Position: candidate for PhD, UT Waco (lab work at Tulane) Current position: instructor of medicine, UTHSCSA Alexander Gelbard, BS 7/05-7/06 Senior Tulane medical student Regulatory T cells in head and neck cancers Current position: intern in ENT surgical oncology, Baylor Medical School Ben Daniel, PhD 5/05-6/07 Project: novel means to deplete regulatory T cells in cancer 17
    • instructor of medicine, UTHSCSA Jens Reuter, MD 8/05-6/07 Fellow, Hematology and Medical Oncology Immunopathogenesis of ovarian cancer Current position: fellow in medical oncology, University of Pennsylvania Rachael Yenni 6/05-6/07 PhD candidate, Graduate Program in Biomedical Sciences Tulane Medical School Novel methods to deplete T regulatory cells Current position: PhD candidate, Graduate Program in Biomedical Sciences (lab change) Current Trainees: Suzanne Thibodeaux, BS Position: MD/PhD student Project: “The role of B7-H1 signals in cancer” Pei Yi Lin, BS Position: PhD student Project: “Non-Treg regulatory cells in cancer”. GRANTS, CONTRACTS AND AWARDS Current: NCI 5R01 CA105207 “Plasmacytoid dendritic cell behavior in ovarian cancer”. My role: PI 15.1%. $1,856,250. 7/15/05 to 6/30/11. FDA R01 FD003118 “Phase II trial of Ontak to treat ovarian cancer under BB-IND 312345”. My role: PI 10% effort. $1,050,000 requested 3/15/06 to 3/14/10 NIH 5R01 AI060424 “A novel MAPK family in T. gondii.” PI: T. Curiel. 10% effort. $1,485,000 4/01/05 to 4/30/11. 3R01 CA105207-02S1 Plasmacytoid dendritic cell behavior in ovarian cancer. PI: Curiel, Tyler J. MD Project Period: 07/27/2005 - 04/30/2010 $151,981 5P30CA54174-16S2. San Antonio Cancer Institute. Role: PI. 6/30/92-6/30/08. $2,700,000 Rippel Foundation “Novel studies of Treg depletion in ovarian cancer”. $270,000 3/06 to 3/08. Role: PI: 2% effort. 18
    • STAR Award no number “Development of novel immunotherapies for cancer”. $1,250,000 12/06 to 12/07. My role: PI. Clavis Pharmaceuticals. A Phase I/II Study of CP-4055 in Patients with Platinum Resistant Ovarian Cancer. PI: T. Curiel. AG013319-15 “Immune dysregulation in aged hosts with cancer.” PI: Curiel, Tyler J. MD Project Period: 4/01/10 – 3/31/13 $1,359,177 Supplement to NIA Barshop Institute “Support Immune effects of rapamycin”. PI: Curiel, Tyler J. MD Project Period: 7/15/09 – 7/14/10 $32,500 Eisai Pharmaceuticals Phase II trial of Ontak plus interferon-α for ovarian cancer. PI: Curiel, Tyler J MD Project Period: 9/01/09 – 8/30/14 $66,000 1 RC2 AG036613-01 “Can Rapamycin Retard Age-Related Diseases.” $225,000 Pending: None Previous: 1. 10/87-9/89 National Research Service Award. Cellular immunity in HIV disease. PI: T. Curiel. Mentor: R.T. Schooley. $95,000. 2. 10/92-6/94 CellPro, Inc. "Immune reconstitution following CD34+ autologous stem cell transplantation." PI: T. Curiel $42,000 3. 9/91-6/94 Immune Response Corp. "CMI to a candidate HIV immunogen". PI: T. Curiel. $280,000 4. 12/92-1/94 Repligen Corp. "Testing of potential HIV vaccines in mice" PI: T. Curiel. $32,000 5. 11/92-2/95 Supplement to 5P30CA-46934. "Immune therapies for B-cell lymphomas" PI: T. Curiel. $117,900 6. 5/92-12/96 NCI R01 AI 27096-04A2 "Toxin gene therapy for AIDS" PI: G.S. Harrison. My role: investigator. $1,300,000. 7. 8/93-9/97 NIAID N01 AI 15123 "Immune studies support for DATRI 002" (CMI in acute HIV infection). PI: T. Curiel. $344,960. 8. 1/94-12/96 NIH 1 U01 AI35231-01. Efficient delivery of HIV-regulated toxin genes for AIDS. PI: G. Harrison. My role: Project leader for SCID mouse and CD34+ stem cell facility. $426,601. 19
    • 9. 3/95-3/98 NCI CA67396-01 "Treatment of AIDS lymphomas with EBV antisense oligos." Role: Co-PI. $1,200,000. 10. 9/96-9/97 NCI. Supplement to 5P30CA-46934. "sFv as gene therapy for AIDS related lymphomas". Role: PI. $75,000. 11. 12/96-11/98 Ligand Pharmaceuticals. "Phase II/III trials of Targretrin in cutaneous T cell lymphoma." My role: PI. $75,000. 12. 10/95-10/97 Amgen, Inc. "Immune support for SCF 940190. “Autologous stem cell support of high dose chemotherapy for breast cancer”. My role: PI. $200,000. 13. 4/1/99-4/1/00 CA78846-01. Subpopulations of human dendritic cells. PI: J. Banchereau, $1,222,286. My role: Investigator (10%). 14. 9/97-8/01 Baylor Research Institute Endowment. My role: PI. 28% effort "Dendritic cells and activation of human T cells". $1,5300,000. 15. 11/95 to 10/02 NIH R01 AI39379 "Human cellular immunity to T. gondii" My role: PI. 35% effort. $1,033,000. 16. 7/01-7/02. DAMD 17-01-1-0479. “The role of the immune cell cytoskeleton in breast cancer immunity: particular relationship between actin and p38 MAP kinase.” My role: mentorPI. $75,000. 17. American Medical Association. “Immunologic consequences of nucleated red blood cells.” Mentor for Janis Taube, Tulane Medical student. $2450. 8/02-12/02 18.American Medical Association. “Role of IL-15 in immunopathogenesis of cutaneous T cell leukemia/lymphoma.” Mentor to Abita Taher, PhD, Tulane Medical Student. $2500. 10/02-2/03. 19. 12/1/01-12/1/03 Golfers against Cancer. “Macrophages and tumor-specific immunity.” My role: PI. 1% effort. $50,000. 20. Alpha Omega Alpha. “Immunologic consequences of nucleated red blood cells.” Mentor for Janis Taube, Tulane Medical student. $3500. 3/03-12/03. 21. American Medical Association. “CD40 expression in cancer immunopathogenesis” Mentor to Alexander Hillel, Tulane Medical Student. $2500. 3/03-12/03. 22. 5/00 to 4/03 NIH R21 AI44322 “DCs and HIV immunity.” $507,000. My role: PI. 20% effort. 20
    • 23. 5U01 CA83014-04 “Tulane AIDS Malignancy Consortium.” PI: E. Zakris. My role: co-investigator. 10% effort. $350,000. 8/1/02 to 7/31/04. 24. Cancer Association of Greater New Orleans. “Biology and immunology of sinonasal undifferentiated carcinoma”. $7500. January 2004 to January 2005. My role: PI. 25. NIH 5R21 DA016029 “Dendritic cell targeted hepatitis C virus treatment”. PI: T. Curiel 5% effort. $510,000. 9/1/02 to 8/31/05. 26. Johnson and Johnson, Inc. “Local delivery of anti-neoplastic agents”. $125,000 3/04 to 3/06. PI: T. Curiel. 2.5 % effort. 27. NCRR M01 RR05096 “Tulane General Clinical Research Center”. PI: T. Curiel. 25% effort. $13,843,595 total direct costs 12/01/01 to 11/30/06. 28. NCI 5R01 CA107974 “Arginase production in cancer: evading immune response” PI: A. Ochoa. My role: co-investigator 2%. $1,4850,000 10/01/04-9/30/09 29. NCI 5R01 CA100425 “SDF-1/CXCR4 signals in ovarian cancer”. PI: T. Curiel. 10% effort. $1,450,000 7/01/04-6/30/09. CLINICAL TRIALS IND holder. PSA vaccine for prostate cancer. 7/00 to 8/03. A clinical trial underwritten by Jenner Biotherapeutics. Principal Investigator. Phase I/II Trial of Ontak to improve tumor immunity in patients with cancer. 9/25/03- Ontak and cancer: BB-IND#11560 Ontak and HCV: BB-IND#11602 (on clinical hold) Phase II trial of Ontak in ovarian cancer: BB-IND#12345 Principal Investigator. Phase II Trial of Ontak to treat refractory epithelial ovarian cancer. 8/10/05- Principal Investigator: Phase II trial of PanVac plus Ontak in refractory ovarian cancer. Trial under development with NCI (James Gulley and Jeff Schlom) and Therion Biologics (Dennis Panacali) BIBLIOGRAPHY Scientific manuscripts: 21
    • 1. Curiel TJ, Perfect JR and Durack DT. Leukocyte subpopulations in cerebrospinal fluid of normal rabbits. Laboratory Animal Science. 1982;32:622-24. 2. Chao BH, Costopoulos DS, Curiel TJ, Bertonis JM, Chisholm P, Williams C, Schooley RT, Rosa JJ, Fisher RA and Maraganore JM. A 113-amino acid fragment of CD4 produced in Escherichia coli blocks human immunodeficiency virus-induced cell fusion. J Biol Chem. 1989;264:5812-5817. 3. Leff JA, Oppegard MA, Curiel TJ, Brown KS, Schooley RT and Repine JE. Progressive increases in serum catalase activity in advancing Human Immunodeficiency Virus infection. Free Radical Biology & Medicine. 1992;13:143-149. 4. Harrison GS, Long CJ, Curiel TJ, Maxwell F and Maxwell I. Inhibition of Human Immunodeficiency Virus-1 (HIV-1) production resulting from transduction with a retrovirus containing an HIV-regulated diphtheria toxin A chain gene. Human Gene Therapy. 1992;3:461-469. 5. Curiel TJ. Tuberculosis in HIV infection. AIDS Newslink. 1992. 6. Curiel TJ, Wong JT, Gorzcyca PF, Schooley RT and Walker BD. CD4+ Human immunodeficiency virus type 1 (HIV-1) envelope-specific cytotoxic T lymphocytes derived from the peripheral blood cells of an HIV-1 infected individual. AIDS Research and Human Retroviruses. 1993;9(1):61-68. 7. McFarland E, Curiel TJ, Rosandich ME, Schoen DJ, Schooley RT and Kuritzkes DR. Cytotoxic T lymphocyte lines specific for Human Immunodeficiency virus type I gag and reverse transcriptase derived from a vertically infected child. Journal of Infectious Diseases. 1993;167(3):719-723. 8. Curiel TJ, Purner MB, Poignard P, Krug EC and Berens RL. Cloned human CD4+ cytotoxic T cells specific for Toxoplasma gondii lyse tachyzoite-infected target cells. J Immunol.1993;151(4):2024-31. 9. Curiel TJ. Risks of Toxoplasmosis to women. Perspectives 1993;1(1):13-14. 10. Shpall EJ, Jones RB, Franklin W, Curiel T, Bitter M, Claman H, Archer P, Bearman SI, Stemmer SM, Myers S, Hami L, Johnson C, Taffs S, Heimfeld S, Hallagan J and Berenson RJ. Transplantation of autologous CD34+ hematopoietic progenitor cells into breast cancer patients following high-dose chemotherapy: Influence of cell source and growth factors on engraftment. J Clin Oncology. 1994;12(1):28-36. 11. Curiel TJ, Nicot D, Wang Y, Ghosh S, Hahn B and Harrison G. Long-term inhibition of clinical and laboratory HIV-1 isolates with a retrovirus encoding an 22
    • HIV-regulated diphtheria toxin A chain gene. Human Gene Therapy. 1993;4(6):741-747. 12. Curiel TJ, Nicot D, Bogedain C, Jilg W, Harrison GS, Cotton M, Curiel DT and Wagner E. Efficient foreign gene expression in Epstein-Barr virus transformed human B-cells. Virology. 1994;198:577-585. 13. Purner MB, Krug EC, Berens RL and Curiel TJ. Epstein-Barr virus transformed B-cells: a potentially convenient antigen presenting cell for propagation of certain human cytotoxic T-cells. Clinical and Diagnostic Laboratory Immunology. 1994;1(6), 696-700. 14. Cook DR, Maxwell IH, Glode LM, Maxwell F, Stevens JO, Purner M, Wagner E, Curiel DT and Curiel TJ. Gene therapy for B-cell lymphoma in a SCID mouse model using an immunoglobulin-regulated diphtheria toxin gene delivered by a novel adenovirus vector. Cancer Biotherapy. 1994;9(2):131-41. 15. Roth G, Curiel TJ, Lacy J. Epstein-Barr viral antigen 1 (EBNA 1) antisense oligonucleotide inhibits proliferation of Epstein-Barr virus-immortalized B cells. Blood. 1994;84(2):582-587. 16. Purner MB, Krug EC, Nash P, Cook DN, Berens RL and Curiel TJ. Cross- reactivity of Human Toxoplasma-specific T Cells: Implications for development of a potential immunotherapeutic or vaccine. J Inf Dis. 1995;171(4):984-991. 17. Finkel TH, Tudor-Williams G, Banda NK, Cotton MF, Curiel TJ, Monks C and Kuper A. Apoptosis occurs in bystander cells and not in productively infected cells of HIV-infected lymph nodes. Nature Medicine. 1995;1:129-134. 18. Harrison GS, Wang Y, Tomczak J, Hogan C, Shpall EJ, Curiel TJ and Felgner PL. Optimization of gene transfer using cationic lipids in cell lines and primary human CD4+ and CD34+ hematopoietic cells. BioTechniques. 1995;19(5):816-823. 19. Dinges MM, Cook DR, King J, Curiel TJ, Zhang X-Q and Harrison GS. HIV- regulated diphtheria toxin A chain gene confers long-term protection against HIV type 1 infection in the human promonocytic cell line U937. Human Gene Therapy. 1995;6:1437-1445. 20. Connick E, Zhang X-Q, Clark SJ, Saag MS, Schooley RT and Curiel TJ. HIV- specific cellular and humoral immune responses in primary HIV infection. AIDS Res Human Retro. 1996;12(12):1129-1140. 21. Purner MB, Berens RL, Nash PB, Ross E, van Linden A, Kruse C, Krug EC and Curiel TJ. CD4-mediated and CD8-mediated cytotoxic and proliferative immune 23
    • responses to Toxoplasma gondii in seropositive humans. Infection & Immunity 1996;64(10):4330-4338. 22. Banda NK, Tomczak JA, Shpall EJ, Sipple J, Steimer K, Hami L, Curiel TJ, and Harrison GS. HIV-gp120 induced cell death in hematopoietic progenitor CD34+ cells. Apoptosis 1997;2:61-68. 23. Cookson ST, Nora JJ, Kithas JA, Arduino MJ, Bond WW, Miller PH, Monahan J, Hoffman RE, Curiel TJ, Kaufman D, Groves BM, Jarvis WR. Pyrogenic reactions in patients undergoing cardiac catheterization associated with contaminated glass medicine cups. Catheterization and Cardiovascular Diagnosis, 1997;42(1):12-18. 24. Curiel TJ. Gene therapies for AIDS-related malignancies. Science & Medicine 1997;4(5):4-5. 25. Kim M, Accavitti MA, Saleh M, Rosenfeld R, Curiel TJ and Curiel DT. Adenoviral vector mediated delivery of the Herpes Simplex virus thymidine kinase gene sensitizes EBV-transformed B cell lines to ganciclovir. Tumor Targeting, 1996;2(4):215-223. 26. Curiel TJ, Kasano K, Piché A and Curiel DT. Gene therapy strategies for AIDS- related malignancies. Gene Therapy, 1997;4:1284-88. 27. Nash PN, Purner MB, Leon RP, Clarke P, Duke RC and Curiel TJ. Toxoplasma gondii infected cells are resistant to multiple inducers of apoptosis. J. Immunol, 1998;160(4):1824-30. 28. Berens RL, Krug EC, Nash PB, and Curiel TJ. Selection and characterization of Toxoplasma gondii mutants resistant to artemisinin. J. Infectious Diseases, 1998;177(4):1128-1131. 29. Purner MB, Berens RL, Tomavo S, Lecordier L, Cesbron-Delauw MF, Kotzin BL, Curiel TJ. Stimulation of human T lymphocytes obtained from Toxoplasma gondii-seronegative persons by proteins derived from T. gondii. J Inf Dis, 1998;177(3):746-753. 30. Kenney JL, Guinness ME, Curiel T, Lacy J. Antisense to the Epstein-Barr virus (EBV)-encoded latent membrane protein 1 (LMP-1) suppresses LMP-1 and BCL-2 expression and promotes apoptosis in EBV-immortalized B-cells, Blood, 1998; 92(5):1721-1727. 31. Piché A, Kasono K, Johaning F, Curiel TJ, Curiel DT. Phenotypic knockout of the latent membrane protein 1 of Epstein-Barr virus by an intracellular single- chain antibody. Gene Therapy, 1998;5:1171-1179. 24
    • 32. Suzuki T, Piche A, Kasono K, Xiang J, Gomez-Navarro J, Moriuchi S, Krisky DM, Oligino T, Glorioso JC, Curiel TJ, Curiel DT. Efficient gene delivery into Epstein-Barr virus (EBV)-transformed human B cells mediated by replication- defective herpes simplex virus-1 (HSV- 1): A gene therapy model for EBV- related B cell malignancy. Biochem Biophys Res Commun, 1998;3:686-690. 33. Tillman BW, de Gruijl TD, Bakker SA, Scheper RJ, Pinedo HM, Curiel TJ, Gerritsen WR and Curiel DT. Maturation of dendritic cells accompanies high- efficiency gene transfer by a CD40-targeted adenoviral vector. J Immunol, 1999;162(11): 6378-6383. 34. Morgan MB, Goldstein NB, Scadden D, Lacy J, Curiel DT, Curiel TJ. Treatment of EBV transformed tumors with antisense oligodeoxynucleotides against EBNA-1 enhances tumor chemosensitivity. Tumor Targeting, 2000;4:278-286. 35. Levy MF, Crippin J, Sutton S, Netto G, McCormack J, Curiel TJ, Goldstein RM, Newman JT, Gonwa TA, Banchereau J, Diamond LE, Byrne G, Logan J, and Klintmalm G. Liver allotransplantation after extracorporeal hepatic support with transgenic (hCD55/hCD59) porcine livers. Transplantation, 2000;69(2):272-280. 36. Zou W-P, Borvak J, Marches F, Wei S, Isaeva T, Curiel TJ. A Guide to Isolation, Culture and Propagation of Dendritic Cells. In “Dendritic Cells: Biology and Clinical Applications” Second Edition. MT Lotze and AW Thomson, eds. Academic Press. London. 2001, pp. 77-96. 37. Zou W, Borvak J, Marches F, Wei S, Galanaud P, Emilie D, Curiel TJ. Macrophage-derived dendritic cells have strong Th1-polarizing potential mediated by β-chemokines rather than IL-12. J Immunol, 2000:165(8):4388-4396. 38. Zou W, Borvak J, Wei S, Curiel DT, Curiel TJ. Reciprocal regulation of plasmacytoid dendritic cells and monocytes during viral infection. Eur J Immunol, 2001(31):3833-3839. 39. Wei S, Marches F, Borvak J, Zou W, Channon J, White M, Radke J, Cesbron- Delauw M, Curiel TJ. Toxoplasma gondii infected human myeloid dendritic cells inhibit T lymphocyte activation and induce contact-dependent apoptosis. Infection and Immunity, 2002;70(4):750-60. 40. Zou W, Machelon V, Coulomb-L’Hermin A, Borvak J, Nome F, Isaeva T, Wei S, Krzysiek R, Durand-Gasselin I, Gordon A, Pustilnik T, Curiel DT, Galanaud P, Capron F, Emilie D, Curiel TJ. Stromal derived factor-1 in human tumors recruits and alters the function of plasmacytoid precursor dendritic cells. Nature Medicine, 2001;7(12):1339-1346. 41. Curiel TJ and Curiel DT. Tumor immunotherapy: Inching towards the finish line. Journal of Clinical Investigation, 2002;109:311-312. 25
    • 42. Wei S, Marches F, Daniels B, Sonda S, Heidenreich K, Curiel TJ. Pyridinylimidazole p38 MAP kinase inhibitory drugs inhibit intracellular Toxoplasma gondii replication. International Journal for Parasitology, 2002; 32(8):969-77. 43. Establishment and characterization of a new mantle cell lymphoma cell line, Lai M, McDonnell T J, O'Connor S L, Medeiros L J, Oudat R, Keating M, Morgan M B, Curiel TJ, R J Ford 2002; Leukemia Research;26:849-55. 44. Zou, W. and Curiel TJ. VLA-5 and transendothelial migration. Nature Medicine 2002;8(8):765-766. [letter] 45. Mudad R, Ramsey M, Kovitz K, Curiel TJ, Hartz R, Nedzi LL, Weiner RS, Zakris EL: Concomitant weekly docetaxel, cisplatin and radiation therapy in locally advanced non-small cell lung cancer: A dose finding study. Lung Cancer, 2003;39(2):173-177. 46. Curiel TJ, Wei S, Dong H, Krzysiek R, Cheng J, Knuston K, Mottram P, Daniel B, Zimmermann M, Borvak J, Gordon A, Dhurandhar N, Myers L, Berggren R, Emilie D, Alvarez R D, Hemminki A, Curiel D T, Chen L, Zou W. Myeloid dendritic cell associated B7-H1 inhibits T cell-mediated anti-tumor immunity. Nature Medicine, 2003;9(5):562-567. 47. Kawakami Y, Curiel TJ, Curiel DT. “Cancer Gene Therapy and Immunotherapy” 2003;Cancer Chemother Biol Response Modif. 21:327-37. 48. Zou W, Wei S and Curiel TJ. “Dendritic Cells” in Gene Therapy. D. Curiel and J. Douglas, eds. Blackwell publishing, in press. 49. Knutson KL, Curiel TJ, Salazar L, Disis ML. “Immunologic Principles and Immunotherapeutic Approaches in Ovarian Cancer”, Hematology and Oncology Clinics of North America, 2003;17(4):1051-1073. 50. La Russa VF, Mondal D, Miller A, Safah H, Rozans M, Curiel TJ, Agrawal K, Weiner R. Neuronal Stem Cells: Biology and Plasticity. Cancer Investigation, 2003;21(5):780-792. 51. Pulendran B, Dillon S, Joseph C, Curiel TJ, Banchereau J, M Mohammadzadeh. Dendritic cells generated in the presence of GM-CSF plus IL-15 prime potent CD8+ Tc1 responses in vivo. Eur J Immunol, 2004;34(1):66-73. 52. Bennouna S, Bliss SK, Curiel TJ, Denkers EY. Cross-talk in the innate immune system: Neutrophils instruct recruitment and activation of dendritic cells during microbial infection. J Immunol 2003;171:6052-8. 26
    • 53. Weldon CB, Parker AP, Patten D, Elliot S, Tang Y, Frigo DE, Dugan CM, Coakley EL, Butler NN, Clayton JL, Alam J, Curiel TJ, Beckman BS, Jaffe BM, Burow ME. Sensitization of Apoptotically-Resistant Breast Carcinoma Cells to TNF and TRAIL by Inhibition of P38 Mitogen-Activated Protein Kinase Signaling. International Journal of Oncology 2004;24(6):1473-1480. 54. Weldon CB, Elliott S, Zhu Y, Clayton JL, Curiel TJ, Jaffe BM, Burow ME. Regulation of estrogen-mediated cell survival and proliferation by p160 coactivators. Surgery 2004;136(2):346-354. 55. Curiel TJ, Cheng P, Mottram P, Alvarez X, Moons L, Evdemon-Hogan M, Wei S, Zou L, Kryczek I, Hoyle G, Lackner A, Carmeliet P, Zou W. Dendritic cell subsets differentially regulate angiogenesis in human ovarian cancer. Cancer Research 2004;64(16):5535-5538. 56. Curiel TJ, Morris C, Brumlik M, Landry SJ, Finstad K, Nelson A, Joshi V, Hawkins C, Alarez X, Lackner A, Mohamadzadeh M. Peptides identified through phage display direct immunogenic antigen to dendritic cells. J Immunol 2004;172(12):7425-31. 57. Curiel TJ, Coukos G, Zou L, Alvarez X, Cheng P, Mottram P, Evdemon-Hogan M, Conejo-Garcia JR, Zhang L, Burow M, Zhu Y, Wei S, Daniel B, Gordon A, Myers L, Disis ML, Knuston K, Lackner A, Chen L, ZouW.. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival Nature Medicine 2004;10(9):942-949. [Featured in News and Views: Shevach, E.M. Fatal attraction: tumors beckon regulatory T cells. Nat Med 10, 900-901 (2004). Among the most cited papers on human regulatory T cells] 58. Brumlik M, Wei S, Finstad K, Nesbit J, Hyman LE, Lacey M, Burow ME, Curiel TJ. Identification of a novel mitogen-activated protein kinase in Toxoplasma gondii. Intl J Parasitol 2004; 34:1245-1254. 59. Zou L, Barnett B, Safah H, LaRussa VF, Evdemon-Hogan M, Mottram P, Wei S, David O, Curiel TJ, Zou W. Bone marrow is a reservoir for CD4+CD25+ regulatory T cells that traffic through CXCL12/CXCR4 signals. Cancer Research, 2004;64(22):8451-8455. 60. Kryczek I, Lange A, Mottram P, Alvarez X, Cheng P, Hogan M, Moons L, Wei S, Zou L, Machelon V, Emilie D, Terrassa M, Lackner A, Curiel TJ, Carmeliet P, Zou W. CXCL12 and vascular endothelial growth factor synergistically induce neoangiogenesis in human ovarian cancers. Cancer Research, 2005;65:465-472. 61. Wei S, Kryczek I, Zou L, Curiel TJ, Cheng P, Zou W. Novel tumor immunotherapy: Targeting dysfunctional antigen presenting cells. Discovery Medicine, 2005;5(29):489-492 27
    • 62. Korokhov N, de Gruijl TD, Aldrich WA, Triozzi PL, Banerjee PT, Gillies SD, Curiel TJ, Douglas JT, Scheper RJ & Curiel DT. High efficiency transduction of dendritic cells by adenoviral vectors targeted to DC-SIGN. Cancer Biol Ther, 2005;4(3):289-94. 63. Wei S, Kryczek I, Zou L, Daniel B, Cheng P, Mottram P, Curiel TJ, Lange A, Zou W. Plasmacytoid dendritic cells induce CD8+ regulatory T cells in human ovarian carcinoma Cancer Res, 2005;62(12):5020-5026. 64. Barnett B, Kryczek I, Cheng P, Zou W, Curiel TJ. Regulatory T cells in ovarian cancer: Biology and therapeutic potential. American Journal of Reproductive Immunology, 2005:54(6):369-377. 65. Combe CL, Curiel TJ, Moretto MM, Khan IA. NK cells help to induce CD8(+)- T-cell immunity against Toxoplasma gondii in the absence of CD4(+) T cells. Infect Immun 2005;73(8): 4913-21 66. Frigo DE, Basu A, Nierth-Simpson E N, Weldon CB, Dugan CM, Elliott S, Collins-Burow BM, Salvo VA, Zhu Y, Melnik LI, Lopez GN, Kushner PJ, Curiel TJ, Rowan BG, McLachlan JA, Burow ME. p38 MAPK stimulates estrogen- mediated transcription and proliferation through the phosphorylation and potentiation of the p160 coactivator GRIP1 Molecular Endocrinology, 2006;20(5):971-983. 67. Zou W and Curiel TJ. “Dendritic cells” in Immunotherapy of Cancer, M. L. Disis, ed. 2006, Humana Press, pages 115-126. 68. Kryczek I, Mottram P, Zou L, Curiel TJ, Zou W. A novel population of myeloid suppressor cells in ovarian cancer mediate immunopathology through B7-H4. Journal of Experimental Medicine, 2006;203(4):871-881 69. Rüter J, Barnett BG, Kryczek I, Coukos G, Zou W, Curiel TJ. Manipulating T regulatory cells in cancer immunotherapy, Expert Opinion in Dermatology, in press 70. Berggren RE, Curiel TJ. After the storm--health care infrastructure in post- Katrina New Orleans. New England Journal of Medicine 2006; 354;15: 1549-1552. 71. Salvo VA, Boue SM, Fonseca JP, Elliott S, Corbitt C, Collins-Burow BM, Curiel TJ, Srivastav SK, Shih BY, Carter-Wientjes C, Wood CE, Erhardt P, Beckman BS, McLachlan JA, Cleveland TE, Burow ME. Antiestrogenic glyceollins suppress human breast and ovarian carcinoma tumorigenesis. Clinical Cancer Research 2006;12(23): 7159-7164. 28
    • 72. Curiel TJ. Murder or Mercy? Hurricane Katrina and the Need for Disaster Training. New England Journal of Medicine, 2006;355(20):2067-2069. 73. Lacey M, Brumlik MJ, Yenni RE, Burow ME, and Curiel TJ. Toxoplasma gondii expresses two mitogen-activated protein kinase genes that represent distinct protozoan subfamilies. J Molec Evolution 2007;64(1):4-14. 74. Curiel TJ. Regulatory T cell development: Is Foxp3 the decider? Nature Medicine 2007;13(3):250-253. 75. Rüter J, Barnett BG, Kryczek I, Brumlik MJ, Daniel BJ, Coukos G, Zou W, Curiel TJ. Altering regulatory T cell function in cancer immunotherapy: A novel means to boost efficacy. Frontiers in Bioscience, in press 76. Rüter J, Barnett BG, Kryczek I, Brumlik MJ, Daniel BJ, Coukos G, Zou W, Curiel TJ. T regulatory cell manipulation in tumor immunotherapy. In: Cancer Immunotherapy. James Hodge, editor. Academic Press, in press 77. Curiel TJ. Treg cells and rethinking cancer immunotherapy. Journal of Clinical Investigation, 2007;117(5):1167-1174. 78. Mary T. Litzinger, Romaine Fernando, Tyler J. Curiel, Douglas W. Grosenbach, Jeffrey Schlom, and Claudia Palena. The IL-2 immunotoxin denileukin diftitox reduces regulatory T cells and enhances vaccine-mediated T-cell immunity, Blood, 2007;110(9): 3192-201 79. Wei, S., Daniel, B. J., Brumlik, M. J., Burow, M. E., Zou, W., Khan, I. A., Wadsworth, S., Siekierka, J., Curiel, T. J. Drugs designed to inhibit human p38 mitogen-activated protein kinase activation treat Toxoplasma gondii and Encephalitozoon cuniculi infection. Antimicrob Agents Chemother 2008;51(12): 4324-8. 80. Tang, Y., Zhao, D. Y., Elliott, S., Zhao, W., Curiel, T. J., Beckman, B. S., Burow, M. E. Epigallocatechin-3 gallate induces growth inhibition and apoptosis in human breast cancer cells through survivin suppression. Int J Oncol 2007;31(4): 705-11. 81. Curiel TJ. Regulatory T cells and treatment of cancer. Current Opinion in Immunology 2008, 20:241–246 82. Barnett BG, Rüter J, Kryczek I, Brumlik MJ, Cheng PJ, Daniel BJ, Coukos G, Zou W, Curiel TJ. 2008. Regulatory T cells: A New Frontier in Cancer Immunotherapy. Adv Exp. Med. Bio. 2008;622:255-260. 83. Coukos, G., W. Zou and T. J. Curiel. “Immune biomarkers” in Prognostic and Predictive Factors in Gynecologic Cancers, in press 29
    • 84. Wei, S., Curiel, T., Coukos, G., Liu, R., Zou, W. 2008. Inhibitory B7 family members in human ovarian carcinoma. Adv Exp Med Biol 622:261-71 85. Padmanabhan, S., Ravella, S., Curiel, T., Giles, F. Current status of therapy for chronic myeloid leukemia: a review of drug development 2008. Future Oncol. 4(3):359-77. 86. Brumlik, M. J., Daniel, B. J., Waehler, R., Curiel, D. T., Giles, F. J., Curiel, T. J. Trends in immunoconjugate and ligand-receptor based targeting development for cancer therapy. 2008 Expert Opin Drug Deliv 5(1):87-103. Manuscripts submitted for publication: Invited speaking engagements Moderator: Immunity to intracellular pathogens. Front Range Workshop "The Host Response to Infections". Denver, CO, May 16, 1997. Host-Pathogen Interplay. International Conference on Toxoplasmosis. Freising, Germany. May 21-25, 2001. Moderator Session, Clinical Oncology. Southern Society for Clinical Investigation. New Orleans, LA. February 20-22, 2003. Session Moderator. Tulane Annual Research Days. April 24-25, 2003. Tulane Medical School, New Orleans, LA. Session Co-Chair. Anti-Tumor Effector Cells and Regulation of Tumor Immunity. American Association of Immunologists Annual Meeting, Denver, CO. May 6-10, 2003. Session Chair: Tumor Immunotherapy. International Conference of Cancer vaccines (co-sponsored by NCI). Bethesda, MD, February 5-7, 2006. Talks: 1. CD4+ HIV-1 envelope specific CTL in an HIV infected individual. AIDS Clinical Trials Group Meeting, Bethesda, MD, September, 1991. 2. Approaches to determination of CTL activity in recipients of a candidate AIDS vaccine. AIDS Clinical Trials Group Meeting, Washington, D.C. March, 1992. 3. Preliminary results of CTL activity in recipients of the Salk HIV vaccine. National Cooperative Vaccine Development Group Meeting, Chantilly, VA. September, 1992. 4. Human Toxoplasmosis. American Association of Veterinary Pathologists Annual Meeting, Minneapolis, MN. July, 1993. 5. Human Toxoplasmosis. Miles Seminar on Toxoplasma Vaccine Development. Kansas City, MO. August 13, 1993. 6. Toxin gene therapy for HIV disease and cancers. UAB Cancer Center Series, Birmingham, AL. September 7, 1993. 30
    • 7. Cellular immune responses in HIV disease. AIDS Center, UAB, Birmingham, AL. September 8, 1993. 8. Gene therapy for AIDS. Emory University School of Medicine. November 29, 1993. 9. Human cellular immunity to the intracellular parasite, Toxoplasma gondii. Immunology lecture series. The National Jewish Center for Immunology and Respiratory Medicine, Denver, Colorado. January 5, 1994. 10. Human cellular immunity to Toxoplasma gondii. Emory Medical School, Infectious Disease research seminar series. June 22, 1994 11. Toxoplasma gondii elicits poor CD8+ cellular immunity in infected humans. Immunology seminar sponsored by Alan Sher and Ricardo Gazzinelli, National Institutes of Health, Bethesda, MD, July 25, 1994. 12. Antigen presentation by Toxoplasma infected cells. Conference Jacques Gonod, Escape mechanisms devised by parasites and Mycobacteria: Possible interference. Aussois, France. September 4-9, 1994. 13. Human Toxoplasmosis: Clinical disease and occupational risks. Keynote address (The Litwak Lecture), North Carolina State School of Veterinary Medicine, Raleigh, NC. September 29, 1994. 14. Antigen processing and presentation by cells infected with Toxoplasma gondii. Presenter and round table discussant. Seventh International Congress of Parasitology, Izmir, Turkey, October 10-14, 1994. 15. Epstein-Barr virus and tumorigenesis. UAB gene therapy series, Birmingham, AB. March 24, 1995. 16. Human cellular immunity to Toxoplasma gondii. Massachusetts General Hospital Infectious Disease Unit Research Seminars Series, Boston, MA. April 18, 1995. 17. Toxoplasma gondii infected cells are resistant to multiple inducers of apoptosis. National Jewish Center for Immunology and Respiratory Medicine, Denver, CO. Research in Progress Series. November 9, 1995. 18. Antigen presentation in Toxoplasma gondii infected cells. INSERM, Lille, France. November 21, 1995. Sponsored by Jean-François Dubremetz. 19. Emerging infectious diseases. Colorado State Legislature April 10, 1996. 20. Human cellular immunity to Toxoplasma gondii. Front Range Workshop "The Host Response to Infections" Denver, CO, May 10, 1996. 21. Cellular immune response to Toxoplasma gondii in Toxoplasma naive individuals. Front Range Workshop "The Host Response to Infections". Denver, CO, May 10, 1996. 22. T. gondii elicits cellular proliferative responses in naive humans. National Jewish Center for Immunology and Respiratory Medicine, Denver, CO. Research in Progress series, October 22, 1996. 23. Inhibition of EBV transforming genes: insights into viral pathogenesis and potential treatment strategies. Baylor Institute for Immunology Research, Dallas, TX. March 25, 1997. 24. An overview of AIDS-related lymphomas. Rocky Mountain Annual Conference on HIV Disease. Denver, CO. February 7, 1997. 31
    • 25. Inhibition of EBV transforming genes: viral pathogenesis and potential for treatment of transformed tumors. Wayne State Medical School, Detroit, MI. May 12, 1997. 26. Human cellular immunity to Toxoplasma gondii. Front Range Workshop "The Host Response to Infections" Denver, CO, May 16, 1997. 27. Cellular immune response to Toxoplasma gondii in Toxoplasma naive individuals. Front Range Workshop "The Host Response to Infections". Denver, CO, May 16, 1997. 28. T. gondii infection and intracellular stress. Front Range Workshop "The Host Response to Infections". Denver, CO, May 16, 1997. 29. HIV infection and the general medicine practitioner. Pueblo Medical Center, Pueblo, CO. May 23, 1997. 30. Human T cell-mediated immunity to Toxoplasma gondii. University of Texas, Southwestern Immunology series. Dallas, TX. May 30, 1997. 31. Considerations of APCs in vaccine development. Vaccine Research Workshop sponsored by Pasteur-Connaught-Merieux, Paris, France. October 23-24, 1997. 32. Dendritic cells in human immune therapy. Transplantation ‘98 Workshop. Dallas, TX. April 29, 1998. EORTC Annual meeting. Functional and phenotypic characteristics of human dendritic cells. Tyler J. Curiel and Jacques Banchereau. Amsterdam, Holland. June 16, 1998. 33. Macrophage derived dendritic cells. University of Alabama, Birmingham, Gene Therapy Dendritic Cell Focus Group Series. January 20, 2000. 34. Novel effector functions of distinct dendritic cell subsets. University of Colorado Health Sciences Center, Cancer Center Grand Rounds, Denver, CO. August 16, 2000. 35. Novel effector functions of distinct dendritic cell subsets. University of Cincinnati Children’s Medical Center Vaccine Series. August 29, 2000. 36. DCs induce IL-12-independent Th1 polarization through b-chemokines. UTSW Oncology Research Program. September 21, 2000. 37. DCs induce IL-12-independent Th1 polarization through b-chemokines: Potential clinical applications. Northwest Biopharmaceuticals Research Program. December 18, 2000. 38. Functional dendritic cells in the tumor microenvironment. University of New Mexico School of Medicine. January 22, 2001. 39. Development of a Comprehensive Cancer Center. Leo W. Jenkins Cancer Center and East Carolina School of Medicine. February 8, 2001. 40. Control of plasmacytoid dendritic cell migration and function. Dermatology Grand Rounds. University of Texas Southwestern School of Medicine. Dallas, TX. March 8, 2001. 41. Dendritic cell migration and function in human tumors. Tulane University Medical School. Special seminar. April 4, 2001. 42. Functional consequences of dendritic cell migration. Tulane Biochemistry Lecture Series. September 9, 2001. 43. Dendritic cell recruitment and function in tumors. Tulane Cancer Center Noon Seminar Series. October 25, 2001. 32
    • 44. Factors governing DC migration. Tulane Gene Therapy Center. November 8, 2001. 45. SDF-1 produced by tumors induces preDC2 to migrate into the tumor microenvironment, and alters preDC2 function. ChemoCentryx invited seminar. San Carlos, CA. November 20, 2001. 46. “MAPK and the control of cell growth: A model using Toxoplasma gondii” Pharmacology Department, Tulane Medical School. December 14, 2001. 47. “DCs and tumor immunity”. Presentation to the Tulane Cancer Center Advisory Board. January 29, 2002 48. “Dendritic Cells: Armour and Sword of Immunity.” Medical Grand Rounds. Tulane University Medical Center, New Orleans, LA. January 30, 2002. 49. “MAPK and control of Toxoplasma gondii replication”. Tulane Molecular and Cell Biology Program “Chalk Talk” program. February 1, 2002. 50. “Immunotherapy for ovarian cancer: What do we know?". Obstetrics and Gynecology Grand Rounds, Tulane Medical School. February 21, 2002. 51. Dendritic Cells and Tumor Immunity. Tulane Surgery Ground Rounds. March 2002. 52. p38 MAPK and the control of cell proliferation. Johnson and Johnson Directed Giving Program Award acceptance speech. Tulane Medical School. March 2002. 53. Dendritic cell functions and differentiation in human tumors. UAB Cancer Center Speaker’s Forum. May 5, 2002. Birmingham, AB. 54. The secret to ultradistance running. Tulane Cancer Center series. September 5, 2002. 55. Novel insights into the immunopathogenesis of ovarian cancer. Fourth Biennial International Conference on Ovarian Cancer. September 19, 2002. 56. p38 MAPK inhibitors and regulation of T. gondii growth. Johnson and Johnson Infectious Disease Group. October 17, 2002. Raritan, NJ. 57. Tulane Medical School Medical Grand Rounds. “A 59 year-old man with a lung mass”. Case discussant. October 30, 2002. New Orleans, LA. 58. “p38 MAPK inhibitors block replication of T. gondii in vitro and protect fatally infected mice.” Tulane Cell Signaling Workshop. New Orleans, LA. November 25, 2002. 59. Update on inhibition of Toxoplasma growth by p38 MAPK inhibitors. Johnson and Johnson Directed Giving Speakers Convention. Raritan, NJ. December 3, 2002. 60. “Cancer Gene Therapy in the Twenty-First Century”. Community Issues in Cancer Management sponsored by Kadlec Medical Center, Richland, WA. March 21, 2003. 61. “Tumor immunology and clinical implications” New Orleans Medical Symposium. New Orleans, LA. April 4, 2003. 62. “Career choices in Academic Medicine”. Noon lecture to Tulane housestaff, May 2003. 63. Zou W and Curiel TJ. Blockade of B7-H1 pathway improves myeloid dendritic cell-mediated anti-tumor immunity. Abstract Number: 3008. American Association of Immunologists Annual Meeting, Denver, CO. May 4-8, 2003. 33
    • 64. Brumlik MJ, Wei S, Burow ME, and Curiel TJ. Identification of gene encoding a novel mitogen-activated protein kinase in Toxoplasma gondii. American Society for Microbiology Southern Meeting, October 23, 2003, New Orleans, LA. 65. “Tumor Immunotherapy: Progress and Problems”. Medical Grand Rounds. Tulane Medical School, February 18, 2004. 66. “Cancer Immunotherapy”. Noon Tulane Medical Residents lecture. Tulane Medical School, New Orleans, LA. March 4, 2004. 67. Brumlik M, Wei S, Lacey M, Curiel TJ. Identification of a novel T. gondii MAP kinase. Keystone Symposium “The Host-Pathogen Standoff”. Taos, NM, March 26-30, 2004. 68. Treg trafficking. “The Host-Pathogen Standoff 69. “A History of Immunotherapy”. C. Thorpe Ray Society Annual Lectureship. New Orleans, LA. March 23, 2004. 70. “Statistical analysis of clinical trials”. Noon lecture to Tulane Medical Oncology Fellows. Tulane Medical School, New Orleans, LA. April 6, 2004. 71. Zou W, Curiel TJ. “Specific recruitment of regulatory T cells fosters immune privilege in ovarian carcinoma” Abstract Number 8380. FASEB Meeting April 17-21, Wash, DC 2004. 72. Weldon CB, Elliott S, Zhu Y, Clayton JL, Curiel TJ, Jaffee BM, Burow ME. Regulation of Estrogen-mediated Cell Survival by p160 coactivators. Society of University Surgeons, February 13, 2004, St. Louis, MO. 73. Novel MAPK family members and their activation in T. gondii. Visiting scientist, Scios Corporation, San Francisco, CA. August 25, 2004. 74. Barnett B and Curiel TJ. Regulatory T cell depletion in human cancer. Marsha Rivkin Biennial Ovarian Cancer Research Symposium. September 25, 2004. Seattle, WA. 75. “When bad things happen to good cells”. Tulane 170th anniversary celebration. Key note address. October 1, 2004. Tulane University, New Orleans, LA. 76. Zou W and Curiel TJ. “Cancer: When bad things happen to good cells.” Mauvernay Grand Prize address. Tulane University, New Orleans, LA. 77. Novel immune-based treatments for ovarian cancer. Vermont Cancer Center Grand Rounds. Burlington, VT. October 13, 2004. 78. AIDS-related malignancies. Vermont Cancer Center Visiting Professor Rounds. Burlington, VT. October 13, 2004. 79. Biologic agents to treat cancer. 98th Annual Meeting of the Southern Medical Association. New Orleans, LA November 11, 2004. 80. Eighth Annual Douglas L. Gordon Memorial Lecture. “Balancing family and career in academic medicine”. 22nd Annual Louisiana Chapter of the American College of Physicians ACP Associates Meeting, January 20, 2005. New Orleans, LA. 81. Curiel TJ. Febrile neutropenia. Fellow noon lecture series. Tulane Medical School. February 7, 2005, New Orleans, LA 82. Curiel TJ. Treg depletion as a novel anti-cancer strategy. National Cancer Institute, Jeffrey Schlom Lab Meeting, February 24, 2005. 34
    • 83. Barnett B and Curiel TJ. Depleting regulatory T cells is associated with improved immunity and tumor clearance in human cancer. Southern Society of Clinical Medicine Annual Meeting. New Orleans, LA. February 25, 2005 84. Brumlik MJ, Wei S, Lacey M, and Curiel TJ. Toxoplasma gondii expresses two distinct mitogen activated protein kinase genes that are differentially regulated. Southern Society of Clinical Medicine Annual Meeting. New Orleans, LA. February 25, 2005 85. Medical Grand Rounds, Columbia University and Rockefeller University Distinguished Lectureship in Immunology series. New York, NY. March 3, 2005. 86. Zou W and Curiel TJ. Novel mechanisms of immune dysfunction in cancer. Keystone Symposium on tumor immunity. March 10, 2005. Keystone, CO. 87. Cancer Center Grand Rounds. Memorial Sloan-Kettering Cancer Center. New York, NY. March 28, 2005. 88. Curiel TJ. Basketballs, science and lofty career goals. Key note address, Alpha Omega Alpha Honor Medical Society Louisiana Alpha Chapter. New Orleans, LA. March 31, 2005. 89. Barnett B, Kryczek I, Wei S, Cheng P, Zou W, Curiel TJ. Ontak depletes functional CD4+CD25+ regulatory T cells in association with improved immunity and tumor clearance in human cancer. Abstract 3226, American Association of Immunologists Annual Meeting, April 2-7, 2005, San Diego, CA. 90. Curiel TJ. Phase I/II trial of Ontak to deplete regulatory T cells in human cancer: an update. Ligand Pharmaceuticals, San Diego, CA. April 5, 2005. 91. Brumlik M and Curiel TJ. Initial characterization of TgMAPK-1, a novel mitogen-activated protein kinase in Toxoplasma gondii. Keystone Symposium on Parasite Drug Development, Copper Mountain, CO, April 9-13, 2005. 92. Barnett B, and Curiel TJ. Depleting regulatory T cells is associated with improved immunity and tumor clearance in human cancer. 2005 American Association for Cancer Research Annual Meeting, Mini-Symposium on Tumor Immunotherapy. Anaheim, California April 16, 2005. Abstract Number 2655. 93. Tyler J. Curiel. Regulatory and effector T cells in cancer. Symposium on anti- tumor immunity. 2005 American Association for Cancer Research Annual Meeting, Anaheim, California April 16, 2005. 94. Tyler J. Curiel. Regulatory T cells as novel immunotherapy targets. Cancer Center Grand Rounds. University of Colorado Health Sciences Center Cancer Center, Aurora, CO. May 13, 2005. 95. Tyler J. Curiel. Regulatory T cells as targets for novel cancer immunotherapy. Alexion Pharmaceuticals Strategic Retreat, Del Mar, CA, May 18, 2005. 96. Tyler J. Curiel. Regulatory T cells in ovarian cancer: Biology and therapeutic implications. Plenary talk at the American Society for Reproductive Immunology, Providence Rhode Island, June 17, 2005. 97. Tyler J. Curiel. The immunopathogenesis of hepatitis C virus infection. Plenary address. Seventh International Symposium on Cytokines and Chemokines, Montreal, Quebec, Canada, September 8, 2005. (cancelled due to Hurricane Katrina) 98. Tyler J. Curiel. Therapeutic potential of Tregs in cancer. GlobeImmune. Aurora, CO, September 27, 2005. 35
    • 99. Tyler J. Curiel. Regulatory T cells in ovarian cancer: Biology and therapeutic implications. Keynote speaker. Fall Southwest Oncology Group (SWOG) meeting, September 30, 2005, New Orleans, LA. (cancelled due to Hurricane Katrina) 100. Tyler J. Curiel. Regulatory T cells in cancer. Plenary address. Cancer Research Institute XIII Annual Meeting on Cancer vaccines. New York, NY, October 6, 2005. 101. Tyler J. Curiel. Regulatory T cells in ovarian cancer. Visiting Professor address at Rush Medical School, Chicago, IL. November 27, 2005. 102. Curiel TJ and Berggren RE. An inside look at Tulane and Charity Hospitals during Hurricane Katrina. Evergreen Rotary Club Meeting. Evergreen, Colorado. November 2005. 103. Tyler J. Curiel. Surviving Katrina: Lessons Learned? Keynote Speaker. University of Colorado Health Sciences Center Symposium on Biomarkers in Prostate Cancer. December 9, 2005. Inverness, Colorado. 104. Curiel TJ and Berggren RE. Medical professionalism and personal preparedness during Hurricane Katrina. Medical Ground Rounds. Colorado Springs, Colorado. December 22, 2005. 105. Tyler J. Curiel. Chemokines in Cancer. Major invited speaker. Keystone Symposium on Chemokines and Chemokine receptors. Snowbird, UT, January 15-20, 2006. 106. Tyler J. Curiel. Regulatory T cell depletion as a novel anti-cancer strategy. International Symposium on Cancer Vaccines. February 5-7, 2006. Washington, DC. 107. Tyler J. Curiel. Cancer Immunopathology. Cancer Center Grand Rounds. University of Colorado Anschutz Cancer Center, Aurora, CO. February 21, 2006. 108. Tyler J. Curiel. T regulatory cells in cancer. National Jewish Hospital Immunology Series. March 15, 2006, Denver, CO. 109. T. J. Curiel. Current status of Ontak to deplete human regulatory T cells. FDA special panel meeting. Bethesda, MD, March 31, 2006. 110. Barnett B and Curiel TJ. Phase II clinical trial of ONTAK in advanced-phase ovarian cancer. AACR Annual Meeting, Washington, DC, April 4, 2006 111. Tyler J. Curiel. Overcoming obstacles to success. Keynote address. Ursuline Academy Athletic Department Banquet. May 3, 2006. New Orleans, LA. 112. Barnett B and Curiel TJ. Phase II trial of Denileukin diftitox to treat advanced stage ovarian cancer. ASCO annual meeting, June 2-6, 2006, Atlanta, GA. 113. Tyler J. Curiel. Regulatory T cells in ovarian cancer. International Symposium on Ovarian Cancer. Crete. June 26-30, 2006. 114. Tyler J. Curiel. Regulatory T cells in tumor immunopathology. UTHSCSA Hematology lecture series. September 19, 2006. 115. Tyler J. Curiel. AIDS related malignancies. 9/28/06. Fellow lecture series. UTHSCSA. 116. Tyler J. Curiel. Delivering medical care in a disaster: inside Tulane and Charity Hospitals during the aftermath of Hurricane Katrina. International Health Club, UTHSCSA. 9/29/06 36
    • 116. Tyler J. Curiel. Novel insights into tumor immunopathology. UTHSCSA Medical Grand Rounds. October 18, 2006 117. Tyler J. Curiel. Ethical decision making in the immediate aftermath of Hurricane Katrina. Conference on Bioethical Decision-Making in Disasters for Area Health Education Consortium (AHEC) in Charleston, SC. Octrober 27, 2006. 118. Tyler J. Curiel. Regulatory T cells in cancer. 18th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, Workshop on "Overcoming critical barriers in immunotherapy". Prague, Czech Republic. November 7-10, 2006. 119. Tyler J. Curiel. The importance of science. Johnson and Johnson Focused Giving Program, New Brunswick, NJ, November 28, 2006. Featured scientist. 120. Tyler J. Curiel. Tumor immunotherapy. UTHSCSA Immunology series. December 8, 2006. 121. Tyler J. Curiel. “Managing Career Development and Team Building in Clinical and Translational Research”. Seminar Series for UTHSCSA Scholars Program. San Antonio, TX. 122. Tyler J. Curiel “New Concepts in Tumor Immunotherapy” Cellular and Structural Biology Seminar Series, UTHSCSA. January 9, 2007. 123. TJ Curiel. “Regulatory T cells in ovarian cancer”. Fourth Biennial Meeting on Mechanism and Therapeutic Reversal of Immune Suppression in Cancer. January 28, 2007. Tampa Florida. 124. TJ Curiel. Developing new drugs for tumor immunotherapy. CTRC phase I drug discovery program. February 21, 2007. San Antonio, TX. 125. TJ Curiel. Depleting immunoregulatory cells as novel cancer immunotherapy. Sidney Kimmel Cancer Center Symposium. Key Note Speaker. San Diego, CA. March 4-7, 2007. 126. TJ Curiel. Novel approaches to tumor immunotherapy. Visiting professor. University of Oklahoma Cancer Center. March 14, 2007 127. TJ Curiel. Mechanisms of tumor-specific immune tolerance. Featured speaker. World Immune Regulation Meeting. Davos, Switzerland. April 15, 2007. 128. TJ Curiel. New approaches to tumor immunotherapy: novel insights. The Robert and Alma Moreton Lectureship in Oncology. Scott and White Medical Center, Temple, TX. June 15, 2007. 129. TJ Curiel. Novel approaches to immune therapy based on recent insights. Eisai Pharmaceuticals visiting scientist. Andover, MA. June 21, 2007. 131. TJ Curiel. Rethinking tumor immunotherapy: New insights from recent discoveries. Aspen Cancer Conference, Aspen, CO. July 18, 2007. 132. TJ Curiel. Disaster preparedness for health care providers: Lessons from Hurricane Katrina. Florence, SC. July 30, 2007. 133. TJ Curiel. Treatment options in Melanoma. Imidex Lecture series. August 1, 2007 Houston, TX. 134. TJ Curiel. Immunotherapy for Melanoma Imidex Lecture series. August 29, 2007. Denver, CO 135. TJ Curiel. Disaster preparedness for health care providers: Lessons from Hurricane Katrina, Iowa, September 15, 2007. 37
    • 136. TJ Curiel. Mechanisms of tumor specific tolerance. UTHSCSA Pharmacology lecture series. San Antonio, TX. October 31, 2007. 137. TJ Curiel. Clinical and immunologic experience with Treg depletion: How can we improve? Eisai Ontak Summit. Princeton, NJ. January 25, 2008. 138. TJ Curiel. Advances in Tumor Immunotherapy. UTHSCSA Biochemistry seminar series. February 2008. 139. TJ Curiel Regulatory T cells as a barrier to cancer immunotherapy. UAB Department of Gene Therapy and Comprehensive Cancer Center Combined Guest Lecture Series. March 3, 2008. Birmingham, AL. 140. TJ Curiel. Regulatory T cells as targets for cancer immunotherapy. CCIR distinguished lecture seminar series at the MD Anderson Cancer Center. Houston, TX. April 11, 2008. 141. TJ Curiel. Crisis leadership: My Katrina experience. Jewish Community Center Leadership Lecture Series. San Antonio, TX. April 16, 2008. 142. TJ Curiel. Regulatory T cells and Tumor Immunotherapy. NCI Tumor Immunology Series, Fredericksburg, MD. May 2, 2008 143. TJ Curiel. Failure as Success. St. Mary’s Hall Commencement address. May 28, 2008. San Antonio, TX. 144. TJ Curiel. Immune Dysregulation in Tumors: Its Basis & Means to Overcome It. June 6, 2008. ACVIM Annual Meeting. State-of-the-Art Lecture Series. San Antonio, TX. 145. TJ Curiel. Novel Insights into Tumor Immunity Predict Novel Approaches to Successful Immunotherapy. ACVIM Annual Meeting. State-of-the-Art Lecture Series. June 6, 2008. San Antonio, TX. 146. TJ Curiel. Regulatory T cells and cancer immunotherapy. Laboratori de Recerca Traslacional Institut Català d´Oncologia Barcelona, SPAIN. June 18, 2008. 147. TJ Curiel. Regulatory T cells in cancer treatment. Aspen Cancer Conference. Aspen, CO. July 20, 2008. 148. Curiel, TJ, “Managing regulatory T cells as a novel cancer treatment strategy” China Tregs 2008 Conference, Beijing, PRC, October 2008. (featured speaker) 149. Curiel, TJ, “Regulatory T Cells and Cancer Immunotherapy” UTSW Simmons Comprehensive Cancer Center Grand Rounds, Dallas, TX, November 2008 (visiting professor) Upcoming Invited Talks Atlanta Shawna Wall, Duane Jeansonne, Pei-Yi Lin, Aijie Liu, Gaby Rennebeck, Suzanne Thibodeaux, Carolina Livi, Ben Daniel, Tyler Curiel. Effects of Interferon-alpha on Regulatory T-cell Depletion in Cancer Immunotherapy. Cytokines 2008. Seventh joint conference of the International Society for Interferon and Cytokine Research and International Cytokine Society. Montreal, Canada. October 12-16, 2008. Abstract number PP11-340. , 38
    • 39